Antibody-Drug Conjugates (ADC) are one of the most promising and fastest growing therapeutical approaches to treat specific cancer types. Due to their special peculiarity, they should only target and kill tumor cells without effecting healthy cells. To ensure this specific and highly targeted binding to degenerated cells, a precise knowledge of the structure and binding properties of the antibody component is of utmost importance.

Our bioanalytical service includes a broad range of state-of-the-art bioanalytical services to identify the structural as well as the functional characterization of ADCs allowing us to provide you with a suitable analytical package for your analytical challenge.

Besides an in-depth analysis of the protein primary structure, post translational modifications, the drug-antibody ratio (DAR) and the level of aggregation, we are experts in analyzing the functional properties of your lead molecules via customized cell-based assays and surface plasmon resonance (SPR) analysis.

Our vast experience and deep knowledge in this field allows us to guide you through the variety of available methods and help you find the optimal analytical solution for your project.

In accordance with your needs, we adapt and, if required, qualify (according to ICH guidelines) our platform methods tailored to your drug substance (DS), its individual formulation matrix and your distinct analytical question.

Get in contact with us to quickly find the optimal setup for your analytical challenge and to speak directly from expert to expert.